Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease January 5, 2026 8:00 AM EST

Company Participants

Jennifer Fox - Chief Business Officer & CFO Leon Moulder - CEO & Chairman of the Board Lisa von Moltke - Head of Research & Development and Chief Medical Officer

Conference Call Participants

Jiale Song - Jefferies LLC, Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Judah Frommer - Morgan Stanley, Research Division Yu Fan - Wedbush Securities Inc., Research Division Brandon Frith - Wolfe Research, LLC

Presentation

Operator

Good morning, everyone. Welcome to the Zenas Biopharma Conference Call. [Operator Instructions] Be advised that this call is being recorded at the company’s request, and a replay will be available in the Investors section of the company’s website following the call.

I’ll now turn the call over to Jennifer Fox, Chief Business Officer and Chief Financial Officer of Zenas. Jennifer, you may begin.

Jennifer Fox Chief Business Officer & CFO

Thank you, operator, and thank you all for joining us to discuss the top line results of our registrational Phase III INDIGO trial for obexelimab for the treatment of immunoglobulin G4-related disease or IgG4-RD. Before we begin, I would like to remind you of the disclaimer outlined on Slide #2.

During today’s presentation, including during the question-and-answer portion of the call, we will be making certain forward-looking statements. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. Forward-looking statements speak only as of the date of this call and involve risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements.

These risks are